Table 2.
Choice Made by Leading Experts of Prognostic Markers at Baseline and After Treatment Start in MZL to be Evaluated in the Near Future
| N = 74 | ||
|---|---|---|
| Prognostic markers at baseline | ||
| NGS | 48 (65%) | |
| TP53 | 43 (58%) | |
| NOTCH2 | 30 (41%) | |
| KLF2 | 19 (26%) | |
| KMT2D | 16 (22%) | |
| TNFAIP3 | 15 (20%) | |
| PTPRD | 5 (7%) | |
| Other | 2 (3%) | |
| PET-CT | 39 (53%) | |
| TMTV | 25 (34%) | |
| SUVmax | 16 (22%) | |
| Deauville score | 14 (19%) | |
| Any measurement | 9 (12%) | |
| Other | 3 (4%) | |
| cfDNA | 29 (39%) | |
| Cytogenetics | 21 (28%) | |
| del(17p) | 11 (15%) | |
| t(11;18) | 11 (15%) | |
| t(14;18) | 8 (11%) | |
| del(7q) | 5 (7%) | |
| t(1;14) | 5 (7%) | |
| +3 | 3 (4%) | |
| +18 | 3 (4%) | |
| 6q23- | 2 (3%) | |
| Any abnormality | 6 (8%) | |
| Other | 1 (1%) | |
| Other | 6 (8%) | |
| Prognostic markers during follow-up | ||
| PET-CT | 42 (57%) | |
| Deauville score | 23 (31%) | |
| TMTV | 17 (23%) | |
| ∆SUVmax | 14 (19%) | |
| SUVmax | 13 (18%) | |
| ∆TMTV | 8 (11%) | |
| Any measurement | 9 (12%) | |
| Other | 3 (4%) | |
| cfDNA | 41 (55%) | |
| ∆cfDNA baseline-EOT | 24 (32%) | |
| ∆cfDNA baseline-interim | 20 (27%) | |
| cfDNA levels | 14 (19%) | |
| Any measurement | 7 (10%) | |
| Other | 1 (1%) | |
| MRD | 27 (36%) | |
| Sample: Blood | 21 (78%) | |
| Sample: Bone marrow | 6 (22%) | |
| Technique: Flow cytometry | 14 (52%) | |
| Technique: PCR | 13 (48%) | |
| Other | 2 (3%) | |
Statistics presented: n(%).
cfDNA = cell-free DNA; EOT = end-of-treatment; NGS = next-generation sequencing; PCR = polymerase chain reaction; PET-CT = 18FDG-Positron emission tomography-computed tomography; SUVmax = Maximum Standardized Uptake Value; TMTV = total metabolic tumor volume.